6 February 2016

Sheeran shines on Romanian trials

James Crux

Brian Sheeran, chairman of green technology company Virotec, delivered some good news to investors today with exciting news of trials in Romania of its Bauxsol waste water cleaning technology.

Sheeran and Dr David McConchie, a fellow director and the group's chief scientific consultant, had just visited Baia Mare in Romania, joining other Virotec staff who were treating 3 million litres of Acid Mine Drainage (AMD) with the group's Bauxsol technology. 'We've had large enquiry levels from Europe', said Sheeran, 'and were invited to Baia Mare by Romanian mining company Remin to do trials'.

Formerly a mining venture Down Under, Virotec (VTI) has worldwide marketing and distribution rights to 'Bauxsol', a 'green' technology that neutralises acid and removes heavy metals from environmentally contaminated water. Although the actual results have not been released yet, McConchie hinted at positive news. 'The initial trials gave fantastic results', he added. 'Our aim at Virotec is not only to protect the environment but to do it in an economically appealing way that will save mining companies money'.

All of this should have impressed observers from the United Nations Environment Programme, the European Union in Brussels and the London Stock Exchange who attended the Romanian trials. Significantly, the pair also boasted that the United States EPA is also currently trialling the technology. 'Trials in the US should be completed by December and we're hopeful of gaining EPA approval for the product for America', said Sheeran.

Virotec, already quoted on the Australian Stock Exchange, listed on Aim in July following a placing of 27.5 million new shares at 14p raising £3.36 million net. 'We came to Aim to internationalise the technology and be first to market', explained Sheeran. W H Ireland was broker to the float.

Today the shares were unchanged at 12.25p.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Forbidden focuses on selling

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair!

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

Plexus hammered by oil industry shutdown

In the middle of 2014 Plexus (AIM: POS) was riding high with a share price of 320p giving the company a market value of £270 million. Today’s profit warning has seen the shares slump 40 per cent to just 73p, valuing Plexus at a mere £65 million. As an engineering company selling mainly into the oil industry, we shouldn’t be too surprised by downgrades. But the severity is startling.

Fusionex shares plunge on hidden profit warning

Malaysian big data software specialist Fusionex (AIM: FXI) has released an upbeat results statement for the year to September. As well as beating historic forecasts, the new financial year is said to have started “on a very strong note… the outlook for 2016 and beyond is very positive”. Sounds fantastic! Yet by this afternoon the shares had collapsed by 35 per cent.

More News